| Position | Action |
|---|---|
| Current AAPL position | Trim 35-40% of exposure immediately |
The Friday rout is a supply-driven shakeout, not a structural breakdown—Apple's unmatched balance sheet, accelerating earnings growth (+28.7% YoY), and $115B annualized capital return create a compelling risk-reward at $308 with defined downside to ~$278 and upside to $340+.
| Indicator | Value | Signal |
|---|---|---|
| Close | $308.91 | bearish |
| 10 EMA | $327.24 | bearish |
| 50 SMA | $309.50 | neutral |
| 200 SMA | $277.66 | bullish |
| RSI | 43.25 | bearish |
| RSI (prior session) | 61.66 | — |
| RSI (2026-07-29) | 66.79 | — |
| MACD | 6.89 | bearish |
| MACD Signal | 8.26 | — |
| MACD Histogram | -1.37 | bearish |
| MACD Histogram Peak (2026-07-17) | +3.33 | — |
| Bollinger Middle (20 SMA) | $324.37 | bearish |
| Bollinger Upper | $344.51 | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Trim 35-40% of AAPL exposure immediately, rotating capital toward AI beneficiaries while preserving residual position with explicit stop loss and re-entry criteria
The trim sizing of 35-40% addresses the prior lesson that when three independent risk vectors converge into an event with negative skew already priced, sizing must match conviction magnitude — capturing direction without capturing magnitude still produces negative alpha. Capital rotates toward AI beneficiaries where the narrative is actively rewarding, not into cash. The franchise floor ($107B FCF, 200 SMA at $278) preserves optionality on mean reversion, but multiple compression risk (32.28x forward P/E, 42.55x P/B) and balance sheet stress (inventory doubled QoQ to $11.1B, current ratio at 1.003) validate the reduced exposure. Price target of $285 reflects the base case scenario; $245-250 remains a low-probability tail case given only 12% recession odds.
Q3 FY2026 earnings prove accelerating operating leverage, not demand weakness
↩ rebuts: “Bear interpretation of guidance miss as demand recession”
· concedes: Bears correctly identify single-day 7.4% drop was large and technically concerning; RSI momentum reset could extend further before stabilization; Supply constraints are real and will limit September quarter unit shipments; Forward P/E of 32x is not cheap relative to historical Apple multiples
Apple faces a multi-quarter earnings headwind from memory cost inflation (2-4pp gross margin compression, $4-9B quarterly gross profit impact), multiple compression risk in a hawkish Fed environment (35x trailing P/E vulnerable to compression toward 28x), and AI narrative rotation away from the stock—all while technicals are breaking down (MACD bearish cross, RSI momentum collapse, 50 SMA support razor-thin at $0.59).
· concedes: The business itself is great (agreed with bull on fundamentals); Trailing quarter was strong (+16.4% revenue, +28.7% EPS); Still premium organic growth at 20-22%; $62B liquidity is enormous in absolute terms
→ vs conservative: Using 200 SMA at $277.66 as support is like citing solid foundation while second floor collapses; implicitly accepts 10% additional drawdown before technical repair begins in a stock with 32x forward P/E and 42.5x P/B
→ vs conservative: Waiting for 'successful retest' with bullish reversal candle before acting means being $20 lower by the time confirmation forms; not risk management, just hoping
→ vs conservative: HOLD thesis requires believing 200 SMA will catch falling knife in hawkish Fed environment with deteriorating fundamentals and rotated narrative
→ vs neutral: 'Setup is mixed, wait for confirmation' is worst possible advice in name that just lost most valuable company crown; AI rotation is happening in real time, capital already moving
→ vs neutral: By the time neutral analyst gets confirmation, stock will have given back another 15-20% as multiple compresses toward 25x earnings
→ vs neutral: Klarna lease-to-own financing partnership is a tell that company admits upgrade cycle is creaking, not a strategic masterstroke
| Bollinger Lower | $304.22 | bearish |
| ATR | $9.87 | bearish |
| ATR (prior) | $8.06 | — |
| Volume | 132.3M | bearish |
| Intraday Low | $300.00 | — |
| Prior Day Close | $333.43 | — |
Support: — | Resistance: —
Short-term trend broken with bearish MACD crossover and RSI collapsed from 66.79 to 43.25 in two sessions. Critical support at 50 SMA ($309.50); a close below $300 would target the 200 SMA at $277.66. Long-term uptrend intact per rising 200 SMA. High volatility confirmed by ATR spike to $9.87. Volume of 132.3M suggests capitulation rather than structural distribution, often preceding short-term relief bounces if $304–$309 support holds.
Market Cap
$4.537 trillion
P/E (TTM)
35.47
Forward P/E
32.28
PEG Ratio
2.72
Price-to-Book
42.55
EPS (TTM)
$8.71
Forward EPS
$9.57
Dividend Yield
0.35%
52-Week High
$344.57
52-Week Low
$201.50
50-Day MA
$309.50
200-Day MA
$277.96
Revenue (TTM)
$466.82B
Gross Profit (TTM)
$227.12B
EBITDA (TTM)
$167.96B
Net Income (TTM)
$128.93B
Gross Margin
~48.7%
Operating Margin
32.6%
Net Profit Margin
27.6%
ROE
148.75%
ROA
27.08%
Free Cash Flow (TTM)
$106.88B
Total Assets
$383.27B
Total Liabilities
$275.75B
Stockholders' Equity
$107.52B
Long-Term Debt
$71.34B
Cash & Equivalents
$39.54B
Short-Term Investments
$22.86B
Total Liquidity (Cash + ST Inv)
$62.40B
Net Debt
$44.80B
Current Ratio
1.003
Operating Cash Flow (Q3 FY26)
$34.37B
Free Cash Flow (Q3 FY26)
$31.91B
CapEx (Q3 FY26)
-$2.46B
Buybacks (Q3 FY26)
-$25.11B
Dividends (Q3 FY26)
-$4.04B
Total Capital Returned (Q3 FY26)
$29.15B
Diluted Share Count (Q3 FY26)
14.71B
YoY Share Reduction
~1.6%
Revenue YoY (Q3 FY26)
+16.4%
Net Income YoY (Q3 FY26)
+27.1%
EPS YoY (Q3 FY26)
+28.7%
Inventory (Q3 FY26)
$11.09B
Working Capital (Q3 FY26)
$0.49B
Strengths
Concerns
Apple Inc. remains a fundamentally elite business with accelerating top-line growth (16.4% YoY), best-in-class profitability (32.6% operating margin, $106.88B TTM FCF), and unmatched cash flow generation. However, the stock is priced for perfection at ~35x trailing earnings and ~42.5x book value, with an extremely thin working capital cushion (current ratio 1.003). The risk/reward at current levels favors patient holders over new entrants. Traders should monitor inventory trends, regulatory developments, and the next product cycle as key catalysts.